XML 21 R12.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Share-Based Payments | 9 Months Ended
--- | ---
Jan. 31, 2022
Share-based Payment Arrangement [Abstract] |
Share-Based Payments | Share-Based Payments The Company has in place a 2021 Equity Incentive Plan, 2010 Equity Incentive Plan and 2008 Equity Incentive Plan. In general, these plans provide for stock-based compensation in the form of (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights to the Company’s employees, directors and non-employees. The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards. Stock-based compensation expense was recognized as follows (table in thousands):
| Three Months Ended January 31, |  | Nine Months Ended January 31, |  |
| 2022 |  | 2021 |  | 2022 |  | 2021 |  |  |  |
General and administrative | $ | 223 |  |  | $ | 149 |  |  | $ | 442 |  |  | $ | 206 |  |  |  |  |
Sales and marketing | 53 |  |  | 51 |  |  | 149 |  |  | 148 |  |  |  |  |
Research and development | 3 |  |  | 7 |  |  | 17 |  |  | 16 |  |  |  |  |
Cost of oncology services | 31 |  |  | 25 |  |  | 116 |  |  | 67 |  |  |  |  |
Total stock-based compensation expense | $ | 310 |  |  | $ | 232 |  |  | $ | 724 |  |  | $ | 437 |  |  |  |  |
Stock Option Grants Black-Scholes assumptions used to calculate the fair value of options granted during the three and nine months ended January 31, 2022 and 2021 were as follows:
| Three Months Ended January 31, |  | Nine Months Ended January 31, |  |
| 2022 |  | 2021 |  | 2022 |  | 2021 |  |  |  |
Expected term in years | 6 |  | 3 |  | 6 |  | 3-6 |  |  |  |
Risk-free interest rates | 1.11%-1.20% |  | 0.12% |  | 0.82%-1.20% |  | 0.12%-0.39% |  |  |  |
Volatility | 64.37%-64.62% |  | 74.98% |  | 64.37%-66.21% |  | 72.64%-74.98% |  |  |  |
Dividend yield | —% |  | —% |  | —% |  | —% |  |  |  |
The weighted average fair value of stock options granted during the three months ended January 31, 2022 and 2021 was $5.80, respectively, and, $5.56 and $5.08 for the nine months ended January 31, 2022 and 2021, respectively. The Company’s stock options activity for the nine months ended January 31, 2022 was a s follows:
| Directors and Employees | Non- Employees |  |  | Total |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Life (Years) |  | Aggregate Intrinsic Value
Outstanding, April 30, 2021 | 1,618,231 |  | 35,415 |  |  |  | 1,653,646 |  |  | $ | 3.96 |  |  | 5.42 |  | $ | 11,384,000 |
Granted | 155,552 |  | 10,500 |  |  |  | 166,052 |  |  | 9.44 |  |  | 9.59 |  |
Exercised | (103,875) |  | — |  |  |  | (103,875) |  |  | 2.24 |  |  |  |  |
Forfeited | (20,500) |  | — |  |  |  | (20,500) |  |  | 7.14 |  |  |  |  |
Canceled | (8,875) |  | — |  |  |  | (8,875) |  |  | 4.83 |  |  |  |  |
Expired | — |  | (5,000) |  |  |  | (5,000) |  |  | 9.60 |  |  |  |  |
Outstanding, January 31, 2022 | 1,640,533 |  | 40,915 |  |  |  | 1,681,448 |  |  | 4.54 |  |  | 5.22 |  | $ | 6,611,000 |
Vested and expected to vest as of January 31, 2022 | 1,640,533 |  | 40,915 |  |  |  | 1,681,448 |  |  | 4.54 |  |  | 5.22 |  | $ | 6,611,000 |
Exercisable as of January 31, 2022 | 1,288,349 |  | 4,584 |  |  |  | 1,292,933 |  |  | 3.77 |  |  | 4.31 |  | $ | 6,057,000 |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration